Biogen Inc. BIIB
Verdict: Sell. Fair value $175 against a price of $188 on 12 Jan 2026, 7% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Revenue declined from $9.84B in 2023 to $9.68B in 2024 (-1.6%), indicating top-line pressure.... Significant volatility in OCF/NI ratio: 0.45 in 2022 (poor) vs 1.76 in 2024 (strong). Suggests....
Main risks
- Persistent Revenue Decline: The company's top line is shrinking, with a 3-year CAGR of -4.1%, indicating pressure on its core product portfolio.
- Extremely Inefficient Working Capital: A Cash Conversion Cycle of 427 days, driven by a massive 431 Days Inventory Outstanding, ties up significant cash and is worsening year-over-year.
- Poor Incremental Returns on Capital: The estimated 3-year ROIIC is -1.2%, suggesting that capital allocation has been value-destructive as the company shrinks its capital base without a corresponding increase in profitability.
- Significant volatility in OCF/NI ratio: 0.45 in 2022 (poor) vs 1.76 in 2024 (strong). Suggests...
- Intense competitive environment
- Significant volatility in OCF/NI ratio: 0.45 in 2022 (poor) vs 1.76 in 2024 (strong). Suggests earnings are heavily impacted by non-operating or one-time items.